[go: up one dir, main page]

EP2483307A1 - Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren - Google Patents

Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren

Info

Publication number
EP2483307A1
EP2483307A1 EP10761113A EP10761113A EP2483307A1 EP 2483307 A1 EP2483307 A1 EP 2483307A1 EP 10761113 A EP10761113 A EP 10761113A EP 10761113 A EP10761113 A EP 10761113A EP 2483307 A1 EP2483307 A1 EP 2483307A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
acid sequence
antibody
seq
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10761113A
Other languages
English (en)
French (fr)
Inventor
Vidadi Yusibov
Vadim Mett
Jessica Chichester
Lauren Goldschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibio Inc
Original Assignee
Fraunhofer USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer USA Inc filed Critical Fraunhofer USA Inc
Publication of EP2483307A1 publication Critical patent/EP2483307A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • This invention relates to influenza hemagglutinin antibodies, and to materials and methods for making and using influenza hemagglutinin antibodies.
  • Influenza has a long history characterized by waves of pandemics, epidemics, resurgences and outbreaks. Influenza is a highly contagious disease that could be equally devastating both in developing and developed countries.
  • the influenza virus presents one of the major threats to the human population. In spite of annual vaccination efforts, influenza infections result in substantial morbidity and mortality. Although flu epidemics occur nearly every year, inevitably pandemics do not occur very often. However, recent flu strains have emerged such that we are again faced with the potential of an influenza pandemic.
  • Avian influenza virus of the type H5 1 currently causing an epidemic in poultry in Asia as well as regions of Eastern Europe, has persistently spread throughout the globe.
  • the virus is highly pathogenic, resulting in a mortality rate of over fifty percent in birds as well as the few human cases which have been identified. If the virus were to achieve human to human transmission, it would have the potential to result in rapid, widespread illness and mortality.
  • Subtypes of the influenza virus are designated by different HA and NA resulting from antigenic shift. Furthermore, new strains of the same subtype result from antigenic drift, or mutations in the HA or NA molecules which generate new and different epitopes. While technological advances have improved the ability to produce improved influenza antigens vaccine compositions, there remains a need to provide additional sources of protection against to address emerging subtypes and strains of influenza.
  • This document relates to antibody compositions and methods for producing antibody compositions, including production in plant systems.
  • This document further relates to vectors encoding antibodies or antigen binding fragments thereof, as well as fusion proteins, plant cells, plants, compositions, and kits comprising antibodies or antigen binding fragments thereof, and therapeutic and diagnostic uses in association with influenza infection in a subject.
  • This document is based in part on the identification of anti-H5 l hemagglutinin monoclonal antibodies (mAbs) that specifically inhibit hemagglutination of highly pathogenic avian influenza (HPAI).
  • mAbs anti-H5 l hemagglutinin monoclonal antibodies
  • HPAI highly pathogenic avian influenza
  • the protective efficacy of one of these antibodies has been demonstrated in animal challenge models (e.g., mouse models) using homologous virus.
  • the specific and effective inhibition of these antibodies makes them useful as therapeutic tool in the treatment and/or prevention of human infection.
  • the mAbs can be a useful diagnostic tool for typing suspected H5 1 human isolates in conjunction with other diagnostic approaches.
  • this document provides antibodies against influenza
  • hemagglutinin antigens as well as antibody components produced in plants.
  • the antibodies can inhibit hemagglutination.
  • antibody compositions that are reactive against influenza hemagglutinin antigen.
  • methods for production and use of the antibodies and compositions are provided herein.
  • this document features an isolated monoclonal antibody that binds hemagglutinin, wherein the antibody has the ability to inhibit hemagglutination, and wherein the antibody is selected from the group consisting of an antibody comprising a light chain variable region amino acid sequence at least 85% identical to the amino acid sequence as set forth in amino acids 1-97 of SEQ ID NO:79 and a heavy chain variable region amino acid sequence at least 85% identical to the amino acid sequence as set forth in amino acids 1- 115 of SEQ ID NO:78; and an antibody comprising a light chain variable region amino acid sequence at least 85% identical to the amino acid sequence as set forth in amino acids 1-96 of SEQ ID NO:81 and a heavy chain variable region amino acid sequence at least 85% identical to the amino acid sequence as set forth in amino acids 1-1 12 of SEQ ID NO:80.
  • the antibody can have a light chain variable region amino acid sequence at least 90% identical to the amino acid sequence as set forth in amino acids 1-97 of SEQ ID NO:79, and a heavy chain variable region amino acid sequence at least 90% identical to the amino acid sequence as set forth in amino acids 1-1 15 of SEQ ID NO:78.
  • the antibody can have a light chain variable region amino acid sequence at least 95% identical to the amino acid sequence as set forth in amino acids 1-97 of SEQ ID NO:79, and a heavy chain variable region amino acid sequence at least 95% identical to the amino acid sequence as set forth in amino acids 1- 115 of SEQ ID NO:78.
  • the antibody can have a light chain variable region amino acid sequence at least 98% identical to the amino acid sequence as set forth in amino acids 1-97 of SEQ ID NO:79, and a heavy chain variable region amino acid sequence at least 98% identical to the amino acid sequence as set forth in amino acids 1-115 of SEQ ID NO:78.
  • the antibody can have a light chain variable region amino acid sequence at least 99% identical to the amino acid sequence as set forth in amino acids 1-97 of SEQ ID NO:79, and a heavy chain variable region amino acid sequence at least 99% identical to the amino acid sequence as set forth in amino acids 1-115 of SEQ ID NO:78.
  • the antibody can have a light chain variable region amino as set forth in amino acids 1-97 of SEQ ID NO:79, and a heavy chain variable region amino acid sequence as set forth in amino acids 1-115 of SEQ ID NO:78.
  • the antibody can have a light chain variable region amino acid sequence at least 90% identical to the amino acid sequence as set forth in amino acids 1-96 of SEQ ID NO:81, and a heavy chain variable region amino acid sequence at least 90% identical to the amino acid sequence as set forth in amino acids 1-1 12 of SEQ ID NO: 80.
  • the antibody can have a light chain variable region amino acid sequence at least 95% identical to the amino acid sequence as set forth in amino acids 1-96 of SEQ ID NO:81, and a heavy chain variable region amino acid sequence at least 95% identical to the amino acid sequence as set forth in amino acids 1- 112 of SEQ ID NO:80.
  • the antibody can have a light chain variable region amino acid sequence at least 98% identical to the amino acid sequence as set forth in amino acids 1-96 of SEQ ID NO:81, and a heavy chain variable region amino acid sequence at least 98% identical to the amino acid sequence as set forth in amino acids 1-112 of SEQ ID NO: 80.
  • the antibody can have a light chain variable region amino acid sequence at least 99% identical to the amino acid sequence as set forth in amino acids 1-96 of SEQ ID NO:81, and a heavy chain variable region amino acid sequence at least 99% identical to the amino acid sequence as set forth in amino acids 1-112 of SEQ ID NO:80.
  • the antibody can have a light chain variable region amino as set forth in amino acids 1-96 of SEQ ID NO:81, and a heavy chain variable region amino acid sequence as set forth in amino acids 1-112 of SEQ ID NO: 80.
  • this document features an antibody that binds hemagglutinin, wherein the antibody has the ability to inhibit hemagglutination, and wherein the antibody is selected from the group consisting of an antibody comprising a light chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO:79 and a heavy chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO:78; and an antibody comprising a light chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO: 80.
  • the antibody can have a light chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 79 and a heavy chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the antibody can have a light chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:79, and a heavy chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the antibody can have a light chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:79 and a heavy chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the antibody can have a light chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:79 and a heavy chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the antibody can have a light chain amino acid sequence as set forth in SEQ ID NO:79 and a heavy chain amino acid sequence as set forth in SEQ ID NO:78.
  • the antibody can have a light chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 81 and a heavy chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 80.
  • the antibody can have a light chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the antibody can have a light chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the antibody can have a light chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 80.
  • the antibody can have a light chain amino acid sequence as set forth in SEQ ID NO:81 and a heavy chain amino acid sequence as set forth in SEQ ID NO:80.
  • any of the antibodies featured herein can be an scFv, Fv, Fab', Fab, diabody, linear antibody or F(ab')2 antigen-binding fragment of an antibody; a CDR, univalent fragment, or a single domain antibody; a human, humanized or part-human antibody or antigen-binding fragment thereof, or a recombinant antibody.
  • the antibody can be produced in a plant.
  • any of the antibodies featured herein can be operatively attached to a biological agent or a diagnostic agent.
  • an antibody can be operatively attached to an agent that cleaves a substantially inactive prodrug to release a substantially active drug.
  • the drug can be an anti-influenza agent.
  • An antibody can be operatively attached to an anti-viral agent (e.g., an anti-influenza agent).
  • An antibody can be operatively attached to a biological agent as a fusion protein prepared by expressing a recombinant vector that comprises, in the same reading frame, a DNA segment encoding the antibody operatively linked to a DNA segment encoding the biological agent.
  • An antibody can be operatively attached to a biological agent via a biologically releasable bond or selectively cleavable linker.
  • An antibody can be operatively attached to a diagnostic, imaging or detectable agent.
  • an antibody can be operatively attached to an X-ray detectable compound, a radioactive ion or a nuclear magnetic spin-resonance isotope.
  • An antibody can be operatively attached to (a) the X-ray detectable compound bismuth (III), gold (III), lanthanum (III) or lead (II); (b) the detectable radioactive ion copper67, gallium67, gallium68, indiuml 11, indiuml l3, iodinel23, iodinel25, iodinel31, mercuryl97, mercury203, rheniuml 86, rheniuml 88, rubidium97, rubidiuml03, technetium99m or yttrium90; or (c) the detectable nuclear magnetic spin-resonance isotope cobalt (II), copper (II), chromium (III), dysprosium (III), erbium (III), gadolinium (III), holmium (III), iron (II), iron (III), manganese (II), neodymium (III), nickel (II), samarium (III), terbium (
  • this document features a nucleic acid comprising a nucleotide sequence encoding an antibody light chain or an antibody heavy chain as provided herein.
  • An expression vector containing the nucleic acid also is provided.
  • the expression vector can further include a nucleotide sequence encoding a leader sequence.
  • This document also features a host cell containing an expression vector as provided herein.
  • the host cell can be a plant cell.
  • this document features a plant comprising a plant cell as provided herein.
  • the plant can be from a genus selected from the group consisting of Brassica, Nicotiana, Petunia, Lycopersicon, Solanum, Capsium, Daucus, Apium, Lactuca, Sinapis, or Arabidopsis .
  • the plant can be from a species selected from the group consisting of Nicotiana
  • the plant can be selected from the group consisting of alfalfa, radish, mustard, mung bean, broccoli, watercress, soybean, wheat, sunflower, cabbage, clover, petunia, tomato, potato, tobacco, spinach, and lentil.
  • the plant can be a sprouted seedling.
  • this document features a recombinant, plant-produced monoclonal antibody that binds hemagglutinin, wherein the antibody has the ability to inhibit hemagglutination, and wherein the antibody is selected from the group consisting of an antibody comprising a light chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO: 79 and a heavy chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO:78; and an antibody comprising a light chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO: 81 and a heavy chain amino acid sequence at least 85 percent identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:79, and a heavy chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:79 and a heavy chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:79 and a heavy chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:78.
  • the recombinant, plant- produced monoclonal antibody can have a light chain amino acid sequence as set forth in SEQ ID NO:79 and a heavy chain amino acid sequence as set forth in SEQ ID NO:78.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the recombinant, plant- produced monoclonal antibody can have a light chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:81 and a heavy chain amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:80.
  • the recombinant, plant-produced monoclonal antibody can have a light chain amino acid sequence as set forth in SEQ ID NO: 81 and a heavy chain amino acid sequence as set forth in SEQ ID NO: 80.
  • this document features a pharmaceutical composition
  • a pharmaceutical composition comprising an antibody as provided herein, and a pharmaceutically acceptable carrier.
  • the composition can be formulated for parenteral or topical administration.
  • the antibody can be a recombinant, plant-produced antibody.
  • the pharmaceutically acceptable composition can be an encapsulated or liposomal formulation.
  • the composition can further comprise a second therapeutic agent.
  • compositions as provided herein for treating an influenza infection in a subject in need thereof, as well as use of a composition as provided herein in the manufacture of a medicament for treating an influenza infection.
  • this document features a method for determining whether a subject is at risk for influenza virus infection.
  • the method can include contacting a biological sample from the subject with an antibody as provided herein.
  • the subject can be a human.
  • this document features a method for typing an influenza virus, comprising contacting the influenza virus with an antibody as provided herein, and if binding of the antibody to the influenza virus is detected, typing the influenza virus as an H5 virus.
  • This document also features a method for treating a subject in need thereof, comprising contacting a biological sample from the subject with an antibody as provided herein and, if the antibody shows detectable binding to the biological sample, administering an antibody as provided herein to the subject.
  • the subject can be a human.
  • the subject can be diagnosed as having influenza.
  • Figure 1 depicts the plant viral vector pGRD4-H5 HA.
  • Figure 2A is a graph depicting the activity of mAb 4F5 against homologous and heterologous strains of influenza viruses.
  • Figure 2B is a graph depicting the activity of mAb 5F5 against homologous and heterologous strains of influenza viruses.
  • Figure 2C is a graph depicting the activity of mAb 1E11 against homologous and heterologous strains of influenza viruses.
  • Figure 3 is a table summarizing hemagglutinin inhibition activity of anti-HA mAbs.
  • Figure 4 is a table summarizing binding activity of anti-HA mAbs.
  • Figure 5 is a table summarizing hemagglutination inhibition activity of anti-H5 HA mAbs.
  • Figure 6 is a table summarizing hemagglutination inhibition activity of anti-H3 HA mAbs.
  • Figure 7 depicts the experimental design used to evaluate the protective efficacy of mAbs in mice.
  • Figure 8 depicts the results of an experiment to evaluate the protective efficacy of mAbs in mice.
  • Figure 9 depicts the amino acid sequences, including signal peptide sequences, of heavy and light chains for mAbs 1E1 1 and 4F5.
  • Figure 10 depicts the amino acid sequences, without signal peptide sequences, of heavy and light chains for mAbs 1E1 1 and 4F5.
  • influenza antibodies that can be useful to prevent, delay onset of, treat, ameliorate symptoms of, reduce occurrence of, and/or diagnose influenza infection.
  • This document also relates to antibody compositions, and methods of production of provided antibody compositions, including but not limited to, production in plant systems. Further, this document relates to vectors, fusion proteins, plant cells, plants and compositions comprising antibodies or antigen binding fragments thereof. Still further provided are kits as well as therapeutic and diagnostic uses in association with influenza infection in a subject.
  • influenza antigens can include any immunogenic polypeptide that elicits an immune response against influenza virus.
  • Immunogenic polypeptides of interest can be provided as independent polypeptides, as fusion proteins, as modified polypeptides [e.g., containing additional pendant groups such as carbohydrate groups, alkyl groups (such as methyl groups, ethyl groups, or propyl groups), phosphate groups, lipid groups, amide groups, formyl groups, biotinyl groups, heme groups, hydroxyl groups, iodo groups, isoprenyl groups, myristoyl groups, flavin groups, palmitoyl groups, sulfate groups, or polyethylene glycol].
  • additional pendant groups such as carbohydrate groups, alkyl groups (such as methyl groups, ethyl groups, or propyl groups), phosphate groups, lipid groups, amide groups, formyl groups, biotinyl groups, heme groups, hydroxyl groups, iodo groups
  • influenza antigen polypeptides for use in accordance with this disclosure have an amino acid sequence that is or includes a sequence identical to that of an influenza polypeptide found in nature; in some embodiments influenza antigen polypeptides have an amino acid sequence that is or includes a sequence identical to a characteristic portion (e.g., an immunogenic portion) of an influenza polypeptide found in nature.
  • full length proteins are utilized as influenza antigen polypeptides in vaccine compositions in accordance with this disclosure.
  • one or more immunogenic portions of influenza polypeptides are used.
  • two or three or more immunogenic portions are utilized, as one or more separate polypeptides or linked together in one or more fusion polypeptides.
  • Influenza antigen polypeptides can include, for example, full-length influenza polypeptides, fusions thereof, and/or immunogenic portions thereof. Where portions of influenza proteins are utilized, whether alone or in fusion proteins, such portions retain immunological activity (e.g., cross-reactivity with anti-influenza antibodies). Based on their capacity to induce immunoprotective response against viral infection, hemagglutinin is an antigen of interest in generating vaccines.
  • full length hemagglutinin is utilized to generate HA antibodies as provided herein.
  • one or more domains of HA can be used.
  • two or three or more domains are utilized, as one or more separate polypeptides or linked together in one or more fusion polypeptides. Sequences of exemplary HA polypeptides are presented in Table 1.
  • ACF47475 A/mallard/Cali 5'MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERG fornia/HKWF IEWNATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCD 1971/2007 QFLEFDADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKES (H7N7) MGFTYSGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQ
  • MCSNGSLQCRICI 3' (SEQ ID N0:8) ABY27653 A/India/m777/ 5'MEKIVLLFAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTV 2007 (H5N1) THAQDILEKKHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCD
  • ABB 6046 A/Indonesia/C 5'DQICIGYHAN STEQVDTIMEKNVTVTHAQDILEKTHNGKL
  • ACD85624 A/Mississippi/ 5'MKTIIALSYILCLVSAQKFPGNDNSTATLCLGHHAVPNGTIV
  • IRCNICI 3' (SEQ ID NO: 11) ACF 10321 A/New 5'MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIV
  • IRCNICI 3' (SEQ ID NO: 14) ACB 11768 A/Indiana/01/2 5'MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNV 008 (H1N1) TVTHSVNLLENSHNGKLCLLKGIAPLQLGNCSVAGWILGNPEC
  • CSNGSLQCRICI 3' (SEQ ID NO:17) ACD85766 A/Indiana/04/2 5'MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNV 008 (H1N1) TVTHSVNLLENNHNGKLCLLKGIAPLQLGNCSVAGWILGNPE
  • ALMVAGLSL WMCSNGSLQCRICI 3' (SEQ ID NO:20) Wyoming 5'MKTIIALSYILCLVFSQKLPGNDNSTATLCLGHHAVPNGTIV H3N2 KTITNDQIE VTNATEL VQ SSSTGGICD SPHQILDGENCTLID ALL
  • ISDN 1258 A/Indonesia/5/ 5'MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTV 73 05 THAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCD
  • CSNGSLQCRICI 3' (SEQ ID NO:23) A/bar-headed 5'MERIVLLLAIVSLVKSDQICIGYHAN STEQVDTIMEKNVTV goose/Qinghai THAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCD /0510/05 EFLNVPEWSYIVEKINPANDLCYPGNFNDYEELKHLLSRINHFE (H5N1) RIQIIPKS S WSDHE AS SGVS S ACPYQGRS SFFR VV WLIKKNNA
  • AASSLAVTLMLAIFIVYMVSRDNVSCSICL 3' (SEQ ID NO:26) ACA28844 A/Brisbane/59 5'MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNV /2007 (H1N1) TVTHSVNLLENSHNGKLCLLKGIAPLQLGNCSVAGWILGNPEC
  • AASSLAVTLMLAIFIVYMVSRDNVSCSICL 3' (SEQ ID NO:29) B/Malaysia/25 5'MKAIIVLLMVVTSNADRIICTGITSSNSPHVVKTATQGEVNV 06/2004-like TGVIPLTTTPTKSHFANLKGTET GKLCPKCLNCTDLDVALG
  • AAP34324 A/New 5'MKAKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNV
  • AAR02640 A/Netherlands 5 ' SKSRGYKMNTQILVFALVASIPTNADKICLGHHAVSNGTKV
  • an influenza antigen polypeptide can have an amino acid sequence that is about 60% identical, about 70% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a sequence selected from the group consisting of SEQ ID NOS: 1-35. In some embodiments, such an influenza antigen polypeptide retains immunogenic activity.
  • an influenza antigen polypeptide can have an amino acid sequence that comprises about 100 contiguous amino acids of a sequence selected from the group consisting of SEQ ID NOS: 1-35.
  • an influenza antigen polypeptide has an amino acid sequence which is about 60% identical, about 70% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 100 amino acids of a sequence selected from the group consisting of SEQ ID NOS: 1-35.
  • an influenza antigen polypeptide can have an amino acid sequence that comprises about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, or more contiguous amino acids of a sequence selected from the group consisting of SEQ ID NOS: 1-35.
  • an influenza antigen polypeptide has an amino acid sequence which is about 60% identical, about 70% identical, about 80% identical, about 85% identical, about 90% identical, about 91% identical, about 92% identical, about 93% identical, about 94% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, or 100% identical to a contiguous stretch of about 150, 200, 250, 300, 350, or more amino acids of a sequence selected from the group consisting of SEQ ID NOS: 1-35.
  • sequences having sufficient identity to influenza antigen polypeptide(s) which retain immunogenic characteristics are capable of binding with antibodies which react with one or more antigens provided herein.
  • Immunogenic characteristics often include three dimensional presentation of relevant amino acids or side groups.
  • One skilled in the art can readily identify sequences with modest differences in sequence (e.g., with difference in boundaries and/or some sequence alternatives, that, nonetheless preserve immunogenic characteristics).
  • HA polypeptides typically contain a transmembrane anchor sequence.
  • HA polypeptides in which the transmembrane anchor sequence has been omitted are
  • HA polypeptide(s) comprising fusion polypeptides which comprise a HA polypeptide (or a portion or variant thereof) operably linked to a thermostable protein.
  • Fusion polypeptides can be produced in any available expression system known in the art.
  • fusion proteins are produced in a plant or portion thereof (e.g. , plant, plant cell, root, or sprout).
  • Enzymes or other proteins that are not found naturally in human or animal cells can be particularly useful in fusion polypeptides as provided herein.
  • thermostable proteins that confer thermostability to a fusion product can be useful. Thermostability can allow a produced protein to maintain its conformation, and maintain produced protein at room temperature. This feature can facilitate easy, time efficient and cost effective recovery of a fusion polypeptide.
  • a representative family of thermostable enzymes that can be used as described herein is the glucanohydrolase family. These enzymes specifically cleave 1,4- ⁇ glucosidic bonds that are adjacent to 1,3- ⁇ linkages in mixed linked polysaccharides (Hahn et ah, 1994 Proc. Natl. Acad.
  • thermostable proteins for use in fusion polypeptides as provided herein include glycosidase enzymes.
  • thermostable glycosidase proteins include those represented by GenBank accession numbers selected from those set forth in Table 2, the contents of each of which are incorporated herein by reference by entire incorporation of the GenBank accession information for each referenced number.
  • Exemplary thermostable enzymes for use in fusion proteins include beta- glucanase enzymes from Clostridium thermocellum, Brevibacillus brevis, and Rhodthermus marinus.
  • Representative fusion proteins can utilize modified thermostable enzymes isolated from Clostridium thermocellum, although any thermostable protein may be similarly utilized.
  • Exemplary thermostable glycosidase proteins are listed in Table 2:
  • Bacillus SLTSPSY KFDCGENRSVQTYGYGLYEV MKPAKNVGIVSS licheniform- FFTYTGPTDGTPWDEIDIEFLGKDTTKVQFNYYTNGVGNHE is KIV LGFDAANSYHTYAFDWQPNSIKWYVDGQLKHTATTQ
  • Paenibacill- KFDCGEYRSTN YGYGLYEVSMKPAKNTGIVSSFFTYTG us polymyxa PSHGTQWDEIDIEFLGKDTTKVQFNYYTNGVGGHEKIINLGF
  • RWVE 3 ' (SEQ ID NO:43) P38645 Beta- 5'MTESAMTSRAGRGRGADLVAAVVQGHAAASDAAGDLSF glucosidase PDGFIWGAATAAYQIEGAWREDGRGLWDVFSHTPGKVASG Thermobis- HTGDIACDHYHRYADDVRLMAGLGDRVYRFSVAWPRIVPD pora GSGPV PAGLDFYDRLVDELLGHGITPYPTLYHWDLPQTLE bispora DRGGWAARDTAYRFAEYALAVHRRLGDRVRCWITLNEPW
  • SEEMLEELVDKIN VE 3' (SEQ ID NO:46) 033830 Alpha- 5'MPSVKIGIIGAGSAVFSLRLVSDLCKTPGLSGSTVTLMDID glucosidase EERLDAILTIAKKYVEEVGADLKFEKTMNLDDVIIDADFVIN Thermotoga TAMVGGHTYLEKVRQIGEKYGYYRGIDAQEFNMVSDYYTF maritima SNY QLKYFVDIARKIEKLSPKAWYLQAANPIFEGTTLVTRT
  • LRH 3' (SEQ ID NO: 50) 052629 ⁇ -galacto- 5'MFPEKFLWGVAQSGFQFEMGDKLRRNIDTNTDWWHWVR sidase DKTNIEKGLVSGDLPEEGINNYELYEKDHEIARKLGLNAYRI Pyrococcus GIEWSRIFPWPTTFIDVDYSY ESY LIEDVKITKDTLEELDEI woesei ANKREVAYYRSVINSLRSKGFKVIV LNHFTLPYWLHDPIEA
  • VKNEAKKK 3' (SEQ ID NO:54)
  • VYAWDVV EAVDPNQPDGLRRSTWYQIMGPDYIELAFKFA
  • QRVGIISWSDPT SWRDPSKFGNLRLIK 3' (SEQ ID NO:55)
  • P33558 Xylanase A 5'MKRKVKKMAAMATSIIMAIMIILHSIPVLAGRIiYDNETGT Clostridium HGGYDYELWKDYGNTIMELNDGGTFSCQWSNIGNALFRKG stercorar- RKFNSDKTYQELGDIVVEYGCDY PNGNSYLCVYGWTRNP ium LVEYYIVESWGSWRPPGATPKGTITQWMAGTYEIYETTRV
  • VDWFVFSKSGT 3' (SEQ ID NO:56)
  • VY ILSVKSNQVKLEVFELENIWL 3' (SEQ ID NO: 60)
  • YLVQVRAGNLVARRRWVSVR 3 (SEQ ID NO:61) Alpha- 5'MLTFHRIIRKGWMFLLAFLLTALLFCPTGQPAKAAAPFNG amylase TMMQYFEWYLPDDGTLWTKVANEANNLSSLGITALWLPPA
  • VSFTEKIFESEP VLEDL WKD S SRLEVD SF YENYD YEINKDEN
  • GIISWSDPTNNSWRDPSKFGNLRLIK 3' (SEQ ID NO:67) AAN05438 Beta- 5'MDDHAEKFLWGVATSAYQIEGATQEDGRGPSIWDAFARR AAN05439 glycosidase PGAIRDGSTGEPACDHYRRYEEDIALMQSLGVRAYRFSVAW
  • YYVDFPSQRRIPKRSALWYRERIARAQL 3' (SEQ ID NO:71) AAD43138 Beta- 5'MKFPKDFMIGYSSSPFQFEAGIPGSEDPNSDWWVWVHDPE glycosidase NTAAGLVSGDFPENGPGYWNLNQNDHDLAEKLGVNTIRVG Thermo- VEWSRIFPKPTFNVKVPVERDENGSIVHVDVDDKAVERLDE sphaera LANKEAV HYVEMYKDWVERGRKLILNLYHWPLPLWLHN aggregans PIMVRRMGPDRAPSGWLNEESVVEFAKYAAYIAWKMGELP
  • thermostable polypeptide can have an amino acid sequence with about 60%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS:36-72. In some embodiments, such a thermostable polypeptide can retain thermostability.
  • thermostable polypeptide can have an amino acid sequence that comprises about 100 contiguous amino acids of a sequence selected from the group consisting of SEQ ID NOS:36-72.
  • a thermostable polypeptide can have an amino acid sequence with about 60%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity to a contiguous stretch of about 100 amino acids from a sequence selected from the group consisting of SEQ ID NOS:36-72.
  • thermostable polypeptide can have an amino acid sequence comprising about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, or more than 700 contiguous amino acids of a sequence selected from the group consisting of SEQ ID NOS:36-72.
  • thermostable polypeptide can have an amino acid sequence with about 60%, about 70%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity to a contiguous stretch of about 150, 200, 250, 300, 350, or more than 350 amino acids from a sequence selected from the group consisting of SEQ ID NO:36-72.
  • antigen fusion partners may be selected which provide additional advantages, including enhancement of immunogenicity, potential to incorporate multiple vaccine determinants, yet lack prior immunogenic exposure to vaccination subjects.
  • Further beneficial qualities of fusion peptides of interest include proteins which provide ease of manipulation for incorporation of one or more antigens, as well as proteins which have potential to confer ease of production, purification, and/or formulation for vaccine preparations.
  • preservation of immunity or preferential qualities therefore may affect, for example, choice of fusion partner and/or choice of fusion location (e.g., N-terminus, C- terminus, internal, combinations thereof).
  • preferences may affect length of segment selected for fusion, whether it be length of antigen or length of fusion partner selected.
  • thermostable carrier molecule LicB also referred to as lichenase
  • LicB 1,3-1,4- ⁇ glucanase (LicB) from Clostridium thermocellum, and has the following amino acid sequence (also set forth in EMBL accession: X63355 [gi:40697]):
  • LicB belongs to a family of globular proteins. Based on the three dimensional structure of LicB, its N- and C-termini are situated close to each other on the surface, in close proximity to the active domain. LicB also has a loop structure exposed on the surface that is located far from the active domain. We have generated constructs such that the loop structure and N- and C-termini of protein can be used as insertion sites for HA polypeptides. HA polypeptides can be expressed as N- or C-terminal fusions or as inserts into the surface loop. Importantly, LicB maintains its enzymatic activity at low pH and at high temperature (up to 75°C).
  • LicB as a carrier molecule contributes advantages, including likely enhancement of target specific immunogenicity, potential to incorporate multiple vaccine determinants, and straightforward formulation of vaccines that may be delivered nasally, orally or parenterally. Furthermore, production of LicB fusions in plants should reduce the risk of contamination with animal or human pathogens. See examples provided herein.
  • Fusion proteins comprising HA polypeptides can be produced in any of a variety of expression systems, including both in vitro and in vivo systems.
  • One skilled in the art will readily appreciate that optimization of nucleic acid sequences for a particular expression system is often desirable.
  • an exemplary optimized sequence for expression of HA polypeptide-LicB fusions in plants is provided, and is shown in SEQ ID NO: 73 :
  • the bold/underlined portion corresponds to the signal sequence
  • the italicized/underlined portion corresponds to the 6X His tag and endoplasmic reticulum retention sequence
  • the two portions in lowercase letters correspond to restriction sites.
  • any relevant nucleic acid encoding a HA polypeptide(s), fusion protein(s), or immunogenic portions thereof is intended to be encompassed within nucleic acid constructs provided herein.
  • transgenic plants expressing HA polypeptide(s) may be utilized.
  • transgenic plants may be produced using methods well known in the art to generate stable production crops.
  • plants utilizing transient expression systems may be utilized for production of HA polypeptide(s).
  • any of nuclear expression, chloroplast expression, mitochondrial expression, or viral expression may be taken advantage of according to the applicability of the system to antigen desired.
  • additional expression systems for production of antigens and fusion proteins can be utilized.
  • mammalian expression systems e.g., mammalian cell lines such as CHO cells
  • bacterial expression systems e.g., E. coif
  • insect expression systems e.g., baculovirus
  • yeast expression systems e.g., reticulate lysates
  • in vitro expression systems e.g., reticulate lysates
  • Influenza antigens can be produced in any suitable system; production is not limited to plant systems.
  • Vector constructs and expression systems are well known in the art and may be adapted to incorporate use of influenza antigens provided herein.
  • influenza antigens can be produced in known expression systems, including mammalian cell systems, transgenic animals, microbial expression systems, insect cell systems, and plant systems, including transgenic and transient plant systems.
  • influenza antigens are produced in plant systems. Plants are relatively easy to manipulate genetically, and have several advantages over alternative sources such as human fluids, animal cell lines, recombinant microorganisms and transgenic animals. Plants have sophisticated post-translational modification machinery for proteins that is similar to that of mammals (although it should be noted that there are some differences in glycosylation patterns between plants and mammals). This enables production of bioactive reagents in plant tissues. Also, plants can economically produce very large amounts of biomass without requiring sophisticated facilities. Moreover, plants are not subject to contamination with animal pathogens. Like liposomes and microcapsules, plant cells are expected to provide protection for passage of antigen to the gastrointestinal tract.
  • Plants may be utilized for production of heterologous proteins via use of various production systems.
  • One such system includes use of transgenic/genetically-modified plants where a gene encoding target product is permanently incorporated into the genome of the plant.
  • Transgenic systems may generate crop production systems.
  • a variety of foreign proteins, including many of mammalian origin and many vaccine candidate antigens, have been expressed in transgenic plants and shown to have functional activity (Tacket et ah, 2000, J. Infect. Dis., 182:302; and Thanavala et ah, 2005, Proc. Natl. Acad. Scl, USA, 102:3378).
  • Another system for expressing polypeptides in plants utilizes plant viral vectors engineered to express foreign sequences (e.g., transient expression). This approach allows for use of healthy non-transgenic plants as rapid production systems.
  • genetically engineered plants and plants infected with recombinant plant viruses can serve as "green factories" to rapidly generate and produce specific proteins of interest. Plant viruses have certain advantages that make them attractive as expression vectors for foreign protein production.
  • RNA viruses have been well characterized, and infectious cDNA clones are available to facilitate genetic manipulation. Once infectious viral genetic material enters a susceptible host cell, it replicates to high levels and spreads rapidly throughout the entire plant.
  • target polypeptides using plant viral expression vectors, including incorporation of target polypeptides into viral genomes.
  • One approach involves engineering coat proteins of viruses that infect bacteria, animals or plants to function as carrier molecules for antigenic peptides. Such carrier proteins have the potential to assemble and form recombinant virus-like particles displaying desired antigenic epitopes on their surface.
  • HA antigens may be produced in any suitable system; production is not limited to plant systems.
  • Vector constructs and expression systems are well known in the art and may be adapted to incorporate use of HA polypeptides provided herein.
  • HA polypeptides can be produced in known expression systems, including mammalian cell systems, transgenic animals, microbial expression systems, insect cell systems, and plant systems, including transgenic and transient plant systems. Particularly where HA polypeptides are produced as fusion proteins, it may be desirable to produce such fusion proteins in plant systems.
  • HA polypeptides are desirably produced in plant systems. Plants are relatively easy to manipulate genetically, and have several advantages over alternative sources such as human fluids, animal cell lines, recombinant microorganisms and transgenic animals. Plants have sophisticated post-translational modification machinery for proteins that is similar to that of mammals (although it should be noted that there are some differences in glycosylation patterns between plants and mammals). This enables production of bioactive reagents in plant tissues. Also, plants can economically produce very large amounts of biomass without requiring sophisticated facilities. Moreover, plants are not subject to contamination with animal pathogens. Like liposomes and microcapsules, plant cells are expected to provide protection for passage of antigen to the gastrointestinal tract.
  • Plants may be utilized for production of heterologous proteins via use of various production systems.
  • One such system includes use of transgenic/genetically-modified plants where a gene encoding target product is permanently incorporated into the genome of the plant.
  • Transgenic systems may generate crop production systems.
  • a variety of foreign proteins, including many of mammalian origin and many vaccine candidate antigens, have been expressed in transgenic plants and shown to have functional activity. (Tacket et ah, 2000, J. Infect. Dis., 182:302; and Thanavala et ah, 2005, Proc. Natl. Acad. Scl, USA, 102:3378; both of which are incorporated herein by reference).
  • One system for expressing polypeptides in plants utilizes plant viral vectors engineered to express foreign sequences (e.g., transient expression). This approach allows for use of healthy non-transgenic plants as rapid production systems. Thus, genetically engineered plants and plants infected with recombinant plant viruses can serve as "green factories" to rapidly generate and produce specific proteins of interest. Plant viruses have certain advantages that make them attractive as expression vectors for foreign protein production. Several members of plant RNA viruses have been well characterized, and infectious cDNA clones are available to facilitate genetic manipulation. Once infectious viral genetic material enters a susceptible host cell, it replicates to high levels and spreads rapidly throughout the entire plant.
  • target polypeptides using plant viral expression vectors, including incorporation of target polypeptides into viral genomes.
  • One approach involves engineering coat proteins of viruses that infect bacteria, animals or plants to function as carrier molecules for antigenic peptides. Such carrier proteins have the potential to assemble and form recombinant virus-like particles displaying desired antigenic epitopes on their surface.
  • This approach allows for time-efficient production of vaccine candidates, since the particulate nature of a vaccine candidate facilitates easy and cost-effective recovery from plant tissue. Additional advantages include enhanced target-specific immunogenicity, the potential to incorporate multiple vaccine determinants, and ease of formulation into vaccines that can be delivered nasally, orally or parenterally.
  • spinach leaves containing recombinant plant viral particles carrying epitopes of virus fused to coat protein have generated immune response upon administration (Modelska et ah, 1998, Proc. Natl. Acad. Set, USA, 95:2481 ; and Yusibov et ah, 2002, Vaccine, 19/20:3155; both of which are incorporated herein by reference).
  • any plants that are amendable to expression of introduced constructs as described herein are useful in accordance with the methods disclosed herein.
  • sprouted seedlings are utilized. As is known in the art, most sprouts are quick growing, edible plants produced from storage seeds.
  • sprouted seedling has been used herein in a more general context, to refer to young plants whether or not of a variety typically classified as “sprouts.” Any plant that is grown long enough to have sufficient green biomass to allow introduction and/or expression of an expression construct as provided for herein (recognizing that the relevant time may vary depending on the mode of delivery and/or expression of the expression construct) can be considered a “sprouted seedling" herein.
  • edible plants are utilized (i.e., plants that are edible by - not toxic to - the subject to whom the protein or polypeptide is to be administered).
  • Any plant susceptible to incorporation and/or maintenance of heterologous nucleic acid and capable of producing heterologous protein can be utilized.
  • a polynucleotide encodes antigen protein whose full activity requires (or is inhibited by) a particular post-translational modification
  • the ability (or inability) of certain plant species to accomplish relevant modification may direct selection.
  • plants are capable of accomplishing certain post-translational modifications (e.g., glycosylation), however, plants will not generate sialyation patterns which are found in mammalian post-translational modification.
  • plant production of antigen may result in production of a different entity than the identical protein sequence produced in alternative systems.
  • crop plants, or crop-related plants are utilized.
  • edible plants are utilized.
  • Plants for use in accordance with the methods provided herein include, for example, Angiosperms, Bryophytes (e.g., Hepaticae and Musci), Pteridophytes (e.g., ferns, horsetails, and lycopods), Gymnosperms (e.g., conifers, cycase, Ginko, and Gnetales), and Algae (e.g., Chlorophyceae, Phaeophyceae, Rhodophyceae, Myxophyceae, Xanthophyceae, and
  • Exemplary plants include members of the families Leguminosae
  • Fabaceae e.g., pea, alfalfa, and soybean
  • Gramineae e.g., corn, wheat, and rice
  • Solanaceae particularly of the genus Lycopersicon (e.g., tomato), Solanum (e.g., potato and eggplant), Capsium (e.g., pepper), Nicotiana (e.g., tobacco); Umbelliferae, particularly of the genus Daucus (e.g., carrot), Apium (e.g., celery), or Rutaceae (e.g., oranges); Compositae, particularly of the genus Lactuca (e.g., lettuce); and Brassicaceae (Cruciferae), particularly of the genus Brassica or Sinapis.
  • Lycopersicon e.g., tomato
  • Solanum e.g., potato and eggplant
  • Capsium e.g., pepper
  • Nicotiana e.g., tobacco
  • useful plants may be species of Brassica or Arabidopsis.
  • Brassicaceae family members include Brassica campestris, B. carinata, B. juncea, B. napus, B. nigra, B. oleraceae, B. tournifortii, Sinapis alba, and Raphanus sativus.
  • Some suitable plants that are amendable to transformation and are edible as sprouted seedlings include alfalfa, mung bean, radish, wheat, mustard, spinach, carrot, beet, onion, garlic, celery, rhubarb, a leafy plant such as cabbage or lettuce, watercress or cress, herbs such as parsley, mint, or clovers, cauliflower, broccoli, soybean, lentils, and edible flowers such as sunflower.
  • a wide variety of plant species may be suitable in the practices described herein.
  • a variety of different bean and other species including, for example, adzuki bean, alfalfa, barley, broccoli, bill jump pea, buckwheat, cabbage, cauliflower, clover, collard greens, fenugreek, flax, garbanzo bean, green pea, Japanese spinach, kale, kamut, kohlrabi, marrowfat pea, mung bean, mustard greens, pinto bean, radish, red clover, soy bean, speckled pea, sunflower, turnip, yellow trapper pea, and others may be amenable to the production of heterologous proteins from viral vectors launched from an agrobacterial construct (e.g., introduced by agroinfiltration).
  • bill jump pea, green pea, marrowfat pea, speckled pea, and/or yellow trapper pea are particularly useful.
  • this document provides production of proteins or polypeptides (e.g., antigens) in one or more of these plants using an agrobacterial vector that launches a viral construct (i.e., an RNA with characteristics of a plant virus) encoding the relevant protein or polypeptide of interest.
  • a viral construct i.e., an RNA with characteristics of a plant virus
  • the RNA has characteristics of (and/or includes sequences of) AIMV.
  • the RNA has characteristics of (and/or includes sequences of) TMV.
  • this document provides young plants (e.g., sprouted seedlings) that express a target protein or polypeptide of interest.
  • the young plants were grown from transgenic seeds; this document also provides seeds which can be generated and/or utilized for the methods described herein. Seeds transgenic for any gene of interest can be sprouted and optionally induced for production of a protein or polypeptide of interest. For example, seeds capable of expressing any gene of interest can be sprouted and induced through: i) virus infection, ii)
  • Seeds capable of expressing a transgene for heavy or light chain of any monoclonal antibody can be sprouted and induced for production of full-length molecule through: i) virus infection, ii) agroinfiltration, or iii) inoculation with bacteria that contain virus genome.
  • Seeds capable of expressing a transgene for one or more components of a complex molecule comprising multiple components such as slgA can be sprouted and used for producing a fully functional molecule through: i) virus infection, ii) agroinfiltration, or iii) inoculation with bacteria that contain virus genome.
  • Seeds from healthy non-trans genie plants can be sprouted and used for producing target sequences through: i) virus infection, ii) agroinfiltration, or iii) inoculation with bacteria that contain a virus genome.
  • the young plants were grown from seeds that were not transgenic. Typically, such young plants will harbor viral sequences that direct expression of the protein or polypeptide of interest. In some embodiments, the plants may also harbor agrobacterial sequences, optionally including sequences that "launched" the viral sequences.
  • vectors may be delivered to plants according to known techniques.
  • vectors themselves may be directly applied to plants (e.g., via abrasive inoculations, mechanized spray inoculations, vacuum infiltration, particle bombardment, or
  • virions may be prepared (e.g., from already infected plants), and may be applied to other plants according to known techniques.
  • viruses A wide variety of viruses are known that infect various plant species, and can be employed for polynucleotide expression (see, for example, in The Classification and
  • these systems include one or more viral vector components.
  • Vector systems that include components of two heterologous plant viruses in order to achieve a system that readily infects a wide range of plant types and yet poses little or no risk of infectious spread.
  • An exemplary system has been described previously (see, e.g., PCT Publication WO 00/25574 and U.S. Patent Publication 2005/0026291, both of which are incorporated herein by reference).
  • viral vectors can be applied to plants (e.g., plants, portions of plant, or sprouts), through infiltration, mechanical inoculation, or spraying, for example. Where infection is to be accomplished by direct application of a viral genome to a plant, any available technique may be used to prepare the genome.
  • ssRNA may be prepared by transcription of a DNA copy of the genome, or by replication of an RNA copy, either in vivo or in vitro.
  • ssRNA vectors may be prepared by in vitro transcription, particularly with T7 or SP6 polymerase.
  • vectors may, for example, trans- complement each other with respect to functions such as replication, cell-to-cell movement, and/or long distance movement.
  • Vectors may contain different polynucleotides encoding HA polypeptides as provided herein. Selection for plant(s) or portions thereof that express multiple polypeptides encoding one or more HA polypeptide(s) may be performed as described above for single polynucleotides or polypeptides.
  • HA polypeptides may be produced in any desirable system.
  • Vector constructs and expression systems are well known in the art and may be adapted to incorporate use of HA polypeptides provided herein.
  • transgenic plant production is known and generation of constructs and plant production may be adapted according to known techniques in the art.
  • transient expression systems in plants are desirable. Two of these systems include production of clonal roots and clonal plant systems, and derivatives thereof, as well as production of sprouted seedlings systems.
  • Clonal roots maintain RNA viral expression vectors and stably produce target protein uniformly in an entire root over extended periods of time and multiple subcultures. In contrast to plants, where a target gene is eliminated via recombination during cell-to-cell or long distance movement, in root cultures the integrity of a viral vector is maintained and levels of target protein produced over time are similar to those observed during initial screening. Clonal roots allow for ease of production of heterologous protein material for oral formulation of antigen and vaccine compositions.
  • clonal entities derived from plants which are useful for production of antigen (e.g., antigen proteins as provided herein) have been described previously and are known in the art (see, for example, PCT Publication WO 05/81905; incorporated herein by reference).
  • Clonal entities include clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants capable of production of antigen (e.g., antigen proteins as described herein).
  • This document further provides methods and reagents for expression of antigen polynucleotide and polypeptide products in clonal cell lines derived from various plant tissues (e.g., roots, leaves), and in whole plants derived from single cells (clonal plants). Such methods are typically based on use of plant viral vectors of various types.
  • this document provides methods of obtaining a clonal root line that expresses a polynucleotide encoding a HA polypeptide, comprising the steps of: (i) introducing a viral vector that comprises a polynucleotide encoding an HA polypeptide as described herein into a plant or portion thereof; and (ii) generating one or more clonal root lines from a plant.
  • Clonal root lines may be generated, for example, by infecting a plant or plant portion (e.g., a harvested piece of leaf) with an Agrobacterium (e.g., A. rhizogenes) that causes formation of hairy roots.
  • Clonal root lines can be screened in various ways to identify lines that maintain virus, or lines that express a polynucleotide encoding a HA polypeptide at high levels, for example.
  • This document further provides clonal root lines, e.g., clonal root lines produced as described herein, and further encompasses methods of expressing polynucleotides and producing polypeptide(s) encoding HA polypeptide(s) using clonal root lines.
  • This document further provides methods of generating a clonal root cell line that expresses a polynucleotide encoding a HA polypeptide, comprising the steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a HA polypeptide; (ii) releasing individual cells from a clonal root line; and (iii) maintaining cells under conditions suitable for root cell proliferation.
  • Clonal root cell lines and methods of expressing polynucleotides and producing polypeptides using clonal root cell lines also are provided herein.
  • this document provides methods of generating a clonal plant cell line that expresses a polynucleotide encoding a HA polypeptide, comprising the steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a HA polypeptide; (ii) releasing individual cells from a clonal root line; and (iii) maintaining cells in culture under conditions appropriate for plant cell proliferation.
  • Also provided herein are methods for generating a clonal plant cell line that expresses a polynucleotide encoding a HA polypeptide comprising the steps of: (i) introducing into cells of a plant cell line maintained in culture a viral vector that comprises a polynucleotide encoding a HA polypeptide; and (ii) enriching for cells that contain viral vector. Enrichment may be performed, for example, by (i) removing a portion of cells from the culture; (ii) diluting removed cells so as to reduce cell concentration; (iii) allowing diluted cells to proliferate; and (iv) screening for cells that contain viral vector.
  • Clonal plant cell lines may be used for production of a HA polypeptide as provided herein.
  • This document provides a number of methods for generating clonal plants, cells of which contain a viral vector that comprises a polynucleotide encoding a HA polypeptide as disclosed herein.
  • this document provides methods of generating a clonal plant that expresses a polynucleotide encoding a HA polypeptide, comprising the steps of: (i) generating a clonal root line, cells of which contain a viral vector whose genome comprises a polynucleotide encoding a HA polypeptide; (ii) releasing individual cells from a clonal root line; and (iii) maintaining released cells under conditions appropriate for formation of a plant.
  • This document further provides methods for generating a clonal plant that expresses a polynucleotide encoding a HA polypeptide, comprising the steps of: (i) generating a clonal plant cell line, cells of which contain a viral vector whose genome comprises a
  • clonal plants as provided herein can express any polynucleotide encoding a HA polypeptide in accordance with this document. Such clonal plants can be used for production of an antigen polypeptide.
  • this document provides systems for expressing a polynucleotide or polynucleotide(s) encoding HA polypeptide(s) in clonal root lines, clonal root cell lines, clonal plant cell lines (e.g., cell lines derived from leaf or stem), and in clonal plants.
  • a polynucleotide encoding a HA polypeptide can be introduced into an ancestral plant cell using a plant viral vector whose genome includes polynucleotide encoding an HA
  • a clonal root line or clonal plant cell line can established from a cell containing virus according to any of several techniques, including those that are further described below.
  • the plant virus vector or portions thereof can be introduced into a plant cell by infection, by inoculation with a viral transcript or infectious cDNA clone, by electroporation, or by T-DNA mediated gene transfer, for example.
  • a "root line” is distinguished from a "root cell line” in that a root line produces actual rootlike structures or roots while a root cell line consists of root cells that do not form rootlike structures.
  • Use of the term "line” is intended to indicate that cells of the line can proliferate and pass genetic information on to progeny cells. Cells of a cell line typically proliferate in culture without being part of an organized structure such as those found in an intact plant.
  • root line is intended to indicate that cells in the root structure can proliferate without being part of a complete plant. It is noted that the term “plant cell” encompasses root cells. However, to distinguish methods for generating root lines and root cell lines from those used to directly generate plant cell lines from non- root tissue (as opposed to generating clonal plant cell lines from clonal root lines or clonal plants derived from clonal root lines), the terms “plant cell” and “plant cell line” as used herein generally refer to cells and cell lines that consist of non-root plant tissue. Plant cells can be from, for example, leaf, stem, shoot, or flower part It is noted that seeds can be derived from clonal plants generated as derived herein. Such seeds may contain viral vector as will plants obtained from such seeds. Methods for obtaining seed stocks are well known in the art (see, for example, U.S. Patent Publication 2004/093643; incorporated herein by reference).
  • This document provides systems for generating a clonal root line in which a plant viral vector is used to direct expression of a polynucleotide encoding a HA polypeptide.
  • One or more viral expression vector(s) including a polynucleotide encoding a HA polypeptide operably linked to a promoter can be introduced into a plant or a portion thereof according to any of a variety of known methods.
  • plant leaves can be inoculated with viral transcripts.
  • Vectors themselves may be directly applied to plants (e.g., via abrasive inoculations, mechanized spray inoculations, vacuum infiltration, particle bombardment, or electroporation).
  • virions may be prepared (e.g., from already infected plants), and may be applied to other plants according to known techniques.
  • ssRNA may be prepared by transcription of a DNA copy of the genome, or by replication of an RNA copy, either in vivo or in vitro.
  • ssRNA vectors can be prepared by in vitro transcription, particularly with T7 or SP6 polymerase. Infectious cDNA clones can be used.
  • Agrobacterially mediated gene transfer can be used to transfer viral nucleic acids such as viral vectors (either entire viral genomes or portions thereof) to plant cells using, e.g., agro infiltration, according to methods known in the art.
  • a plant or plant portion may then be then maintained (e.g., cultured or grown) under conditions suitable for replication of viral transcript.
  • virus spreads beyond the initially inoculated cell, e.g., locally from cell to cell and/or systemically from an initially inoculated leaf into additional leaves. However, in some embodiments, virus does not spread.
  • viral vector may contain genes encoding functional MP and/or CP, but may be lacking one or both of such genes.
  • viral vector is introduced into (infects) multiple cells in the plant or portion thereof.
  • leaves are harvested.
  • leaves may be harvested at any time following introduction of a viral vector.
  • a clonal root culture (or multiple cultures) is prepared, e.g., by known methods further described below.
  • any available method may be used to prepare a clonal root culture from a plant or plant tissue into which a viral vector has been introduced.
  • One such method employs genes that exist in certain bacterial plasmids. These plasmids are found in various species of Agrobacterium that infect and transfer DNA to a wide variety of organisms. As a genus, Agrobacteria can transfer DNA to a large and diverse set of plant types including numerous dicot and monocot angiosperm species and gymnosperms (see, for example, Gelvin, 2003, Microbiol. Mol. Biol. Rev., 67: 16, and references therein, all of which are incorporated herein by reference).
  • the molecular basis of genetic transformation of plant cells is transfer from bacterium and integration into plant nuclear genome of a region of a large tumor- inducing (Ti) or rhizogenic (Ri) plasmid that resides within various Agrobacterial species. This region is referred to as the T-region when present in the plasmid and as T-DNA when excised from plasmid.
  • T-region when present in the plasmid
  • T-DNA when excised from plasmid.
  • a single-stranded T-DNA molecule is transferred to a plant cell in naturally occurring Agrobacterial infection and is ultimately incorporated (in double-stranded form) into the genome.
  • Systems based on Ti plasmids are widely used for introduction of foreign genetic material into plants and for production of transgenic plants.
  • rhizogenes causes development of hairy roots at the site of infection, a condition known as "hairy root disease.” Each root arises from a single genetically transformed cell. Thus root cells in roots are clonal, and each root represents a clonal population of cells. Roots produced by A. rhizogenes infection are characterized by a high growth rate and genetic stability (Giri et al, 2000, Biotech. Adv., 18: 1, and references therein, all of which are incorporated herein by reference). In addition, such roots are able to regenerate genetically stable plants (Giri 2000, supra).
  • this document encompasses use of any strain of Agrobacteria, particularly any rhizogenes strain, that is capable of inducing formation of roots from plant cells.
  • a portion of the Ri plasmid (Ri T-DNA) is responsible for causing hairy root disease. While transfer of this portion of the Ri plasmid to plant cells can conveniently be accomplished by infection with Agrobacteria harboring the Ri plasmid, this document encompasses use of alternative methods of introducing the relevant region into a plant cell. Such methods include any available method of introducing genetic material into plant cells including, but not limited to, biolistics, electroporation, PEG-mediated DNA uptake, and Ti- based vectors.
  • Ri T-DNA can be introduced into plant cells by use of a viral vector.
  • Ri genes can be included in the same vector that contains a polynucleotide encoding a HA polypeptide or in a different viral vector, which can be the same or a different type to that of the vector that contains a polynucleotide encoding a HA polypeptide as provided herein. It is noted that the entire Ri T-DNA may not be required for production of hairy roots, and this document encompasses use of portions of Ri T-DNA, provided that such portions contain sufficient genetic material to induce root formation, as known in the art. Additional genetic material, e.g., genes present within the Ri plasmid but not within T-DNA, may be transferred to a plant cell, particularly genes whose expression products facilitate integration of T-DNA into the plant cell DNA.
  • harvested leaf portions are contacted with A rhizogenes under conditions suitable for infection and transformation.
  • Leaf portions are maintained in culture to allow development of hairy roots.
  • Each root is clonal, i.e., cells in the root are derived from a single ancestral cell into which Ri T-DNA was transferred.
  • a portion of such ancestral cells will contain a viral vector.
  • cells in a root derived from such an ancestral cell may contain viral vector since it will be replicated and will be transmitted during cell division.
  • a high proportion e.g., at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (100%), or substantially all (at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within the clonal root, movement of viral vector within the root is not necessary to maintain viral vector throughout the root. Individual clonal hairy roots may be removed from the leaf portion and further cultured. Such roots are also referred to herein as root lines. Isolated clonal roots continue to grow following isolation.
  • Root lines were tested by Western blot. Root lines displayed a variety of different expression levels of various polypeptides. Root lines displaying high expression were selected and further cultured. These root lines were subsequently tested again and shown to maintain high levels of expression over extended periods of time, indicating stability. Expression levels were comparable to or greater than expression in intact plants infected with the same viral vector used to generate clonal root lines. In addition, stability of expression of root lines was superior to that obtained in plants infected with the same viral vector.
  • Root lines may be cultured on a large scale for production of antigen polypeptides, as discussed further below. It is noted that clonal root lines (and cell lines derived from clonal root lines) can generally be maintained in medium that does not include various compounds, e.g., plant growth hormones such as auxins and cytokinins, that typically are employed in culture of root and plant cells. This feature greatly reduces expense associated with tissue culture, and it may contribute significantly to economic feasibility of protein production using plants.
  • plant growth hormones such as auxins and cytokinins
  • any of a variety of methods may be used to select clonal roots that express a polynucleotide encoding HA polypeptide(s) as provided herein.
  • Western blots, ELISA assays, and other suitable techniques can be used to detect an encoded polypeptide.
  • detectable markers such as GFP
  • alternative methods such as visual screens can be performed.
  • an appropriate selection can be imposed (e.g., leaf material and/or roots derived therefrom can be cultured in the presence of an appropriate antibiotic or nutritional condition and surviving roots identified and isolated).
  • Certain viral vectors contain two or more polynucleotide(s) encoding HA polypeptide(s), e.g., two or more polynucleotides encoding different polypeptides. If one of these is a selectable or detectable marker, clonal roots that are selected or detected by selecting for or detecting expression of the marker will have a high probability of also expressing a second polynucleotide. Screening for root lines that contain particular polynucleotides can also be performed using PCR and other nucleic acid detection methods.
  • clonal root lines can be screened for presence of virus by inoculating host plants that will form local lesions as a result of virus infection (e.g., hypersensitive host plants). For example, 5 mg of root tissue can be homogenized in 50 ⁇ of phosphate buffer and used to inoculate a single leaf of a tobacco plant. If virus is present in root cultures, within two to three days characteristic lesions will appear on infected leaves. This means that root line contains recombinant virus that carries a polynucleotide encoding a HA polypeptide. If no local lesions are formed, there is no virus, and the root line is rejected as negative. This method is highly time and cost efficient.
  • roots that contain virus may be subjected to secondary screening, e.g., by Western blot or ELISA to select high expressers. Additional screens can be applied, such as screens for rapid growth, growth in particular media, or growth under particular
  • screening methods may, in general, be applied in the development of any of clonal root lines, clonal root cell lines, clonal plant cell lines, and/or clonal plants described herein.
  • root cell lines can be generated from individual root cells obtained from a root using a variety of known methods. Such root cell lines may be obtained from various different root cell types within the root. In general, root material is harvested and dissociated (e.g., physically and/or enzymatically digested) to release individual root cells, which are then further cultured. Complete protoplast formation is generally not necessary. If desired, root cells can be plated at very dilute cell
  • Root cell lines derived in this manner are clonal root cell lines containing viral vector. Such root cell lines therefore exhibit stable expression of a polynucleotide encoding a HA polypeptide as provided herein.
  • Clonal plant cell lines can be obtained in a similar manner from clonal roots, e.g., by culturing dissociated root cells in the presence of appropriate plant hormones. Screens and successive rounds of enrichment can be used to identify cell lines that express a
  • cells of a clonal root cell line are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (100%), or substantially all (at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within a clonal root cell line, movement of viral vector among cells is not necessary to maintain viral vector. Clonal root cell lines can be used for production of a polynucleotide encoding a HA polypeptide, as described below.
  • This document provides methods for generating a clonal plant cell line in which a plant viral vector is used to direct expression of a polynucleotide encoding a HA polypeptide as provided herein.
  • one or more viral expression vector(s) including a polynucleotide encoding a HA polypeptide operably linked to a promoter is introduced into cells of a plant cell line that is maintained in cell culture.
  • a number of plant cell lines from various plant types are known in the art, any of which can be used. Newly derived cell lines can be generated according to known methods for use in practicing the methods disclosed herein.
  • a viral vector can be introduced into cells of a plant cell line according to any of a number of methods.
  • protoplasts can be made and viral transcripts then electroporated into cells.
  • Other methods of introducing a plant viral vector into cells of a plant cell line also can be used.
  • a method for generating clonal plant cell lines and a viral vector suitable for introduction into plant cells can be used as follows: Following introduction of viral vector, a plant cell line may be maintained in tissue culture. During this time viral vector may replicate, and polynucleotide(s) encoding a HA polypeptide(s) as provided herein may be expressed.
  • Clonal plant cell lines are derived from culture, e.g., by a process of successive enrichment. For example, samples may be removed from culture, optionally with dilution so that the concentration of cells is low, and plated in Petri dishes in individual droplets. Droplets are then maintained to allow cell division.
  • droplets may contain a variable number of cells, depending on the initial density of the culture and the amount of dilution. Cells can be diluted such that most droplets contain either 0 or 1 cell if it is desired to obtain clonal cell lines expressing a polynucleotide encoding a HA polypeptide after only a single round of enrichment.
  • any appropriate screening procedure can be employed. For example, selection or detection of a detectable marker such as GFP can be used. Western blots or ELISA assays can be used. Individual droplets (100 ⁇ ) contain more than enough cells for performance of these assays. Multiple rounds of enrichment are performed to isolate successively higher expressing cell lines. Single clonal plant cell lines (i.e., populations derived from a single ancestral cell) can be generated by further limiting dilution using standard methods for single cell cloning. However, it is not necessary to isolate individual clonal lines. A population containing multiple clonal cell lines can be used for expression of a polynucleotide encoding one or more HA polypeptide(s).
  • clonal root lines In general, certain considerations described above for generation of clonal root lines apply to the generation of clonal plant cell lines. For example, a diversity of viral vectors containing one or more polynucleotide(s) encoding a HA polypeptide(s) as provided herein can be used as can combinations of multiple different vectors. Similar screening methods can be used. As in the case of clonal root lines and clonal root cell lines, cells of a clonal plant cell line are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division. Thus a high proportion (e.g.
  • the clonal plant cell line can be used for production of a polypeptide encoding a HA polypeptide as described below.
  • Clonal plants can be generated from clonal roots, clonal root cell lines, and/or clonal plant cell lines produced according to various methods described herein. Methods for generation of plants from roots, root cell lines, and plant cell lines such as clonal root lines, clonal root cell lines, and clonal plant cell lines described herein are well known in the art (see, e.g., Peres et al, 2001, Plant Cell, Tissue, Organ Culture, 65:37; incorporated herein by reference; and standard reference works on plant molecular biology and biotechnology cited elsewhere herein).
  • This document therefore provides a method of generating a clonal plant comprising steps of (i) generating a clonal root line, clonal root cell line, or clonal plant cell line according to any of the methods described herein; and (ii) generating a whole plant from a clonal root line, clonal root cell line, or clonal plant.
  • Clonal plants may be propagated and grown according to standard methods.
  • cells of a clonal plant are derived from a single ancestral cell that contains viral vector and will, therefore, also contain viral vector since it will be replicated and will be transmitted during cell division.
  • a high proportion e.g. at least 50%, at least 75%, at least 80%, at least 90%, at least 95%), all (100%), or substantially all (at least 98%) of cells will contain viral vector. It is noted that since viral vector is inherited by daughter cells within the clonal plant, movement of viral vector is not necessary to maintain viral vector.
  • transgenic cell lines or seeds are generated, which are then sprouted and grown for a period of time so that a protein or polypeptide included in the transgenic sequences is produced in young plant tissues (e.g., in sprouted seedlings).
  • Typical technologies for the production of transgenic plant cells and/or seeds include Agrobacterium tumefaciens mediated gene transfer and microprojectile bombardment or electroporation.
  • HA polypeptide(s) are useful for production of HA polypeptide(s) as described herein.
  • This document further provides sprouted seedlings, which may be edible, as a biomass containing a HA polypeptide.
  • biomass is provided directly for consumption of antigen containing compositions.
  • biomass is processed prior to consumption, for example, by homogenizing, crushing, drying, or extracting.
  • HA polypeptides are purified from biomass and formulated into a pharmaceutical composition.
  • the methods can include growing a seed to an edible sprouted seedling in a contained, regulatable environment (e.g., indoors and/or in a container).
  • a seed can be a genetically engineered seed that contains an expression cassette encoding a HA polypeptide, which expression is driven by an exogenously inducible promoter.
  • exogenously inducible promoters can be used that are inducible, for example, by light, heat, phytohormones, and/or nutrients.
  • this document provides methods of producing HA
  • polypeptide(s) in sprouted seedlings by first generating a seed stock for a sprouted seedling by transforming plants with an expression cassette that encodes HA polypeptide using an Agrobacterium transformation system, wherein expression of a HA polypeptide is driven by an inducible promoter.
  • Transgenic seeds can be obtained from a transformed plant, grown in a contained, regulatable environment, and induced to express a HA polypeptide.
  • methods include infecting sprouted seedlings with a viral expression cassette encoding a HA polypeptide, expression of which may be driven by any of a viral promoter or an inducible promoter.
  • Sprouted seedlings can be grown for two to fourteen days in a contained, regulatable environment or at least until sufficient levels of HA polypeptide have been obtained for consumption or harvesting.
  • This document further provides systems for producing HA polypeptide(s) in sprouted seedlings that include a housing unit with climate control and a sprouted seedling containing an expression cassette that encodes one or more HA polypeptides, wherein expression is driven by a constitutive or inducible promoter.
  • Systems can provide unique advantages over the outdoor environment or greenhouse, which cannot be controlled. Thus, this document enables a grower to precisely time the induction of expression of HA polypeptide. It can greatly reduce time and cost of producing HA polypeptide(s).
  • transiently transfected sprouts contain viral vector sequences encoding an HA polypeptide as provided herein. Seedlings can be grown for a time period so as to allow for production of viral nucleic acid in sprouts, followed by a period of growth wherein multiple copies of virus are produced, thereby resulting in production of HA polypeptide(s).
  • genetically engineered seeds or embryos that contain a nucleic acid encoding HA polypeptide(s) are grown to sprouted seedling stage in a contained, regulatable environment.
  • the contained, regulatable environment may be a housing unit or room in which seeds can be grown indoors. All environmental factors of a contained, regulatable environment may be controlled. Since sprouts do not require light to grow, and lighting can be expensive, genetically engineered seeds or embryos may be grown to sprouted seedling stage indoors in the absence of light.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
EP10761113A 2009-09-29 2010-09-29 Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren Ceased EP2483307A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24695809P 2009-09-29 2009-09-29
PCT/US2010/050693 WO2011041391A1 (en) 2009-09-29 2010-09-29 Influenza hemagglutinin antibodies, compositions, and related methods

Publications (1)

Publication Number Publication Date
EP2483307A1 true EP2483307A1 (de) 2012-08-08

Family

ID=43304891

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10761113A Ceased EP2483307A1 (de) 2009-09-29 2010-09-29 Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren

Country Status (4)

Country Link
US (2) US8784819B2 (de)
EP (1) EP2483307A1 (de)
CA (1) CA2776144C (de)
WO (1) WO2011041391A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
WO2015190457A1 (ja) * 2014-06-09 2015-12-17 株式会社カネカ 組換えブレビバチルス属細菌を用いた組換え蛋白質の製造方法
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
PE20190209A1 (es) 2016-04-04 2019-02-07 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y uso de estos
KR20240155978A (ko) 2016-05-05 2024-10-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체
EP3694874A1 (de) 2017-10-11 2020-08-19 Bioverativ USA Inc. Verfahren zur induktion von komplementaktivität
US11702464B2 (en) 2018-03-02 2023-07-18 The University Of Chicago Methods and composition for neutralization of influenza
CA3133152A1 (en) * 2019-03-12 2020-09-17 Perpetuum Cropscience Bvba Cannabinoid precursor production
JP2022521819A (ja) 2019-03-25 2022-04-12 ビステラ， インコーポレイテッド インフルエンザを処置および予防するための組成物および方法
CN110124025B (zh) 2019-04-22 2022-10-25 肇庆大华农生物药品有限公司 一种禽流感与禽腺病毒4型二联基因工程亚单位疫苗及其制备方法
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途
CN113150083B (zh) * 2021-04-29 2023-03-24 山西高等创新研究院 重组禽流感亚单位疫苗及其制备方法
CN119630280A (zh) 2022-05-14 2025-03-14 诺维信公司 用于预防、处理、抑制和/或消除植物病原性侵染和感染的组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154813A1 (en) * 2007-06-15 2008-12-24 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS61176721A (ja) 1985-01-31 1986-08-08 Mochizuki Motor Kk マンホ−ル蓋の開閉運搬装置
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (de) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU684041B2 (en) 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6103511A (en) 1996-10-04 2000-08-15 University Of Georgia Research Foundation, Inc. Lichenase and coding sequences
WO1998014595A1 (en) 1996-10-04 1998-04-09 University Of Georgia Research Foundation Inc. Fungal lichenase and coding sequences
CN100480269C (zh) 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
BR9812272A (pt) 1997-08-05 2000-07-18 Stressgen Biotechnologies Corp Respostas imunológicas contra antìgenos de hpv, eliciadas por composições que compreendem um antìgeno de hpv e uma proteìna de tensão ou um vetor de expressão capaz de expressar essas proteìnas
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
NZ510358A (en) 1998-08-11 2002-09-27 Large Scale Biology Corp Method for recovering proteins from the interstitial fluid of plant tissues
IL142041A0 (en) 1998-10-07 2002-03-10 Syngenta Participations Ag Therapeutically active proteins in plants
EP1077600A4 (de) 1998-10-30 2003-04-09 Univ Jefferson Herstellung von biomedizinischen peptiden und proteinen in pflanzen unter verwendung von pflanzlichen virusvektoren
JP2003517280A (ja) 1999-02-05 2003-05-27 トーマス・ジェファーソン・ユニバーシティ トランス相補性システムを用いての植物における生物医学用ペプチド及びタンパク質の生成
US6734173B1 (en) 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
DK1294892T3 (da) 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
JP2004512264A (ja) 2000-06-26 2004-04-22 ストレスゲン　バイオテクノロジーズ　コーポレイション ヒト乳頭腫ウイルスの治療法
JP2004501648A (ja) 2000-06-26 2004-01-22 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム チオレドキシンおよび目的のポリペプチドの間に融合するユビキチンを含む三重融合タンパク質
US7342002B2 (en) 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
EP2284274B1 (de) 2001-12-26 2015-08-26 University Of Central Florida Expression von Schutzantigenen in transgenen Chloroplasten und Herstellung verbesserter Impfstoffe
CA2475735A1 (en) 2002-02-11 2003-09-18 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20040170606A1 (en) 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
WO2004044161A2 (en) 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
ATE527278T1 (de) 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
EP2192172B1 (de) 2003-02-03 2014-12-03 iBio, Inc. System zur Expression von Genen in Pflanzen
CN101123871B (zh) 2003-05-05 2011-05-18 美国陶氏益农公司 来源于转基因植物细胞的稳定免疫预防性和治疗性组合物及其制备方法
AU2004235813B2 (en) 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CZ297389B6 (cs) 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
EP1682667B1 (de) 2003-11-10 2010-05-26 Icon Genetics GmbH Von rna-virus abgeleitetes pflanzenexpressionssystem
EP2570433A1 (de) 2003-11-14 2013-03-20 Emergent Product Development Gaithersburg Inc. Durch Recall-Technologie erzeugte, neutralisierende menschliche Antikörper für Anthrax-Toxin
PA8621301A1 (es) 2004-01-09 2006-09-22 Pfizer ANTICUERPOS CONTRA MAdCAM
ES2532609T3 (es) 2004-02-20 2015-03-30 Ibio, Inc. Sistemas y métodos para expresión clonales en plantas
ATE530196T1 (de) 2004-03-03 2011-11-15 Iq Therapeutics Bv Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
WO2005111622A2 (en) 2004-04-23 2005-11-24 The University Of Georgia Research Foundation, Inc. Diagnostic assay for trypanosoma cruzi infection
CA2568015C (en) 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP1616959A1 (de) 2004-07-07 2006-01-18 Icon Genetics AG Biologisch sichere transiente Proteinexpression in Pflanzen
EP1885395A4 (de) 2005-05-16 2009-12-02 Merck & Co Inc Verfahren zur verbesserung der immunogenität von plasmodium-antigenen
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
CA2637837A1 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP1984405A4 (de) 2006-02-13 2010-06-30 Fraunhofer Usa Inc Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
US8277816B2 (en) 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007095320A2 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
AU2007215066A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Production of foreign nucleic acids and polypeptides in plant systems
KR101510753B1 (ko) * 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
AU2007261196A1 (en) 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
CN104140958A (zh) 2006-08-09 2014-11-12 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
WO2008033105A1 (en) * 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
KR20090059080A (ko) 2006-09-15 2009-06-10 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
CN103497255B (zh) 2006-10-16 2015-11-11 美国国有健康与人类服务部(马里兰州) 作为疟疾疫苗的恶性疟原虫表面蛋白的偶联物
WO2008061013A2 (en) * 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
FR2911608B1 (fr) 2007-01-23 2009-04-03 Centre Nat Rech Scient Nouvelles compositions vaccinales anti paludique et ses utilisations.
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
US8778348B2 (en) 2007-04-28 2014-07-15 Ibio Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009026397A2 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
KR20090042652A (ko) * 2007-10-26 2009-04-30 주식회사 바이오노트 고병원성 조류 인플루엔자 바이러스 감염증을 위한 항체치료방법
WO2009058355A2 (en) 2007-10-31 2009-05-07 University Of Central Florida Research Foundation, Inc. Chloroplast-derived human vaccine antigens against malaria
KR101304150B1 (ko) * 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
WO2010036970A2 (en) * 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2352751A2 (de) 2008-09-28 2011-08-10 Fraunhofer USA, Inc. Plasmodium-impfstoffe, antigene, zusammensetzungen und verfahren
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154813A1 (en) * 2007-06-15 2008-12-24 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2174957A1 (de) * 2007-06-15 2010-04-14 Xiamen University An das hämagglutinin vom avian influenza virus subtype h5 bindende monoklonale antikörper und anwendungen davon

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FLOSS DOREEN MANUELA ET AL: "Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview", TRANSGENIC RESEARCH, LONDON, GB, vol. 16, no. 3, 1 June 2007 (2007-06-01), pages 315 - 332, XP002615562, ISSN: 0962-8819, [retrieved on 20070414], DOI: 10.1007/S11248-007-9095-X *
METT VADIM ET AL: "Plants as biofactories", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 36, no. 6, 1 November 2008 (2008-11-01), pages 354 - 358, XP002615959, ISSN: 1045-1056, DOI: 10.1016/J.BIOLOGICALS.2008.09.001 *
See also references of WO2011041391A1 *
SHOJI Y ET AL: "Plant-expressed HA as a seasonal influenza vaccine candidate", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 23, 2 June 2008 (2008-06-02), pages 2930 - 2934, XP022666969, ISSN: 0264-410X, [retrieved on 20080409], DOI: 10.1016/J.VACCINE.2008.03.045 *
THROSBY MARK ET AL: "Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 3, no. 12, 1 January 2008 (2008-01-01), pages E3942.1 - E3942.15, XP002615561, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0003942 *
YANG MING ET AL: "Production and diagnostic application of monoclonal antibodies against influenza virus H5", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 162, no. 1-2, 1 January 2009 (2009-01-01), pages 194 - 202, XP002615560, ISSN: 0166-0934, [retrieved on 20090821], DOI: 10.1016/J.VIROMET.2009.08.006 *
YOSHIDA REIKO ET AL: "Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses", PLOS PATHOGENS, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 5, no. 3, 1 March 2009 (2009-03-01), pages e1000350, XP002541080, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000350 *

Also Published As

Publication number Publication date
US20140331366A1 (en) 2014-11-06
WO2011041391A1 (en) 2011-04-07
CA2776144C (en) 2020-10-27
US20120315323A1 (en) 2012-12-13
US9809644B2 (en) 2017-11-07
CA2776144A1 (en) 2011-04-07
US8784819B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
US9809644B2 (en) Influenza hemagglutinin antibodies, compositions and related methods
US9115201B2 (en) Humanized neuraminidase antibody and methods of use thereof
US20080124272A1 (en) Influenza antibodies, compositions, and related methods
US20110059130A1 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
US20120034253A1 (en) Influenza Vaccines, Antigens, Compositions, and Methods
CA2692933C (en) Yersinia pestis antigens, vaccine compositions, and related methods
CA2642054C (en) Influenza antigens, vaccine compositions, and related methods
US8778348B2 (en) Trypanosoma antigens, vaccine compositions, and related methods
US8277816B2 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
US20110314575A1 (en) Plasmodium Vaccines, Antigens, Compositions and Methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IBIO, INC.

17Q First examination report despatched

Effective date: 20150916

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20171020